Study dupilumab skin effects in different ethnic groups
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This Phase 4 study looks at how dupilumab works in people with moderate-to-severe atopic dermatitis (eczema), and whether the mechanism differs across ethnic backgrounds. If you’re eligible, it may help doctors understand who benefits most from dupilumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of atopic dermatitis (eczema) for at least 2 years
- Your eczema must be moderate-to-severe, covering more than 10% of your skin surface, with a doctor score of 3 or 4
- You must be female who can become pregnant and agree to reliable birth control during the study and for 12 weeks after the last dose (or choose true abstinence)
- You weigh at least 30 kilograms (about 66 pounds)
- You must be able and willing to follow all study visits and procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how the body’s “molecular signals” change in the skin after using dupilumab for eczema. It may help researchers understand who benefits most from treatment.
This study looks at how well Dupilumab works over time for people with atopic dermatitis (eczema). It includes adults, teens, and children ages 6 and up.
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
This trial studies why eczema (“atopic dermatitis”) varies in severity even when people receive the medicine dupilumab. It may help doctors better predict who responds well and how to monitor treatment.
This study compares a new injectable medicine (IBI3027) to an approved one (Dupilumab) for people with moderate-to-severe eczema. If you join, you'll receive one of the two treatments to see if the new one works as well for reducing itching and skin symptoms.
This study tests whether combining two drugs, dupilumab and tofacitinib, works better for moderate to severe eczema in adults than either alone. It may help people whose eczema is not well controlled with standard treatments.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.